Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. - Wikidata - wikimedia - TriplyDB

Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.

Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.

http://www.wikidata.org/entity/Q35222112

about

Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential Sézary Syndrome and Atopic Dermatitis: Comparison of Immunological Aspects and Targets Advances in Cancer Immunotherapy in Solid Tumors Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?T-cell lymphomas, a challenging disease: types, treatments, and future.Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents.Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes Blockade of MCP-1/CCR4 signaling-induced recruitment of activated regulatory cells evokes an antitumor immune response in head and neck squamous cell carcinoma Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma.A three-signal model of T-cell lymphoma pathogenesis Mature T-cell leukemias: Molecular and Clinical Aspects.Investigational drugs for T-cell lymphoma.Therapeutic Options for Aggressive T-Cell Lymphomas.What Do Structures Tell Us About Chemokine Receptor Function and Antagonism?Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies.Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor Profile.Sézary syndrome: old enigmas, new targets.Chemokines and their receptors: insights from molecular modeling and crystallography.Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders.Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering.Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma.Gene expression analysis in Cutaneous T-Cell Lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicators.New Targeted Treatments for Cutaneous T-cell Lymphomas.CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells.Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab.Therapeutic Antibodies to KIR3DL2 and Other Target Antigens on Cutaneous T-Cell Lymphomas.Mogamulizumab treatment of refractory peripheral T-cell lymphoma following autologous stem cell transplantation: A case report.Acute lymphoblastic leukemia cells create a leukemic niche without affecting the CXCR4/CXCL12 axis.Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials.Low-dose total skin electron beam therapy for cutaneous lymphoma : Minimal risk of acute toxicities.Mogamulizumab for the treatment of T-cell lymphoma.Recent advances in systemic targeted therapy for cutaneous T-cell lymphoma.Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome.BET bromodomain inhibitor JQ1 decreases CD30 and CCR4 expression and proliferation of cutaneous T-cell lymphoma cell lines.S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 2: Treatment and Follow-up (ICD10 C82 - C86).Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection.Sézary syndrome managed with histone deacetylase inhibitor followed by anti-CCR4 monoclonal antibody.Synchronous Occurrence of Mycosis Fungoides, Diffuse Large B Cell Lymphoma and Acute Myeloid Leukemia.

P2860

Q26744275-C2C1B2B5-4C9E-4CF5-8A6F-041CA7EA1B19 Q26746551-6B57143E-D840-466C-8AF6-D388EFAA6FFD Q28080113-C8F12379-6E84-40E9-A81C-E928509C82AA Q30239965-D3F1C05B-B5DE-41DB-A140-3E6E173E9C5A Q30244553-67FA78D4-49AE-4647-82A7-5B3124FDB3ED Q34516083-61A1CF18-886D-471C-82FE-16C9B0341A2F Q36793430-11B83532-C644-40B3-BF90-C9513E7924CC Q37437275-EEA1207F-4000-4DD1-97B3-32099B617D1C Q37723390-DFFA6F1E-73B7-42EC-B8F8-8D5002CBDE69 Q38434473-0E36EA6F-4A52-41E4-8147-ABBD38BE32BD Q38593164-F350E498-43BB-4420-89E3-3677C46D39C9 Q38598546-5791264F-4401-474C-89EC-CB94EA3E554B Q38635909-F7F56C7F-01BE-467E-BA42-BFEA75EF7E4B Q38675843-FAFAF7D5-67DA-4CBB-B600-A2229090601B Q38680670-48D4EC5E-1269-4264-ADE2-FF213FC04991 Q38702312-74B21A78-EB1E-4B88-9065-CEF3A4707D27 Q38752663-4CE29081-E6F3-47ED-827D-7FA5B839EE26 Q38772711-530456D2-82EE-4E49-BC44-761235452D3A Q38908803-20F07706-5FC0-4BCD-9E36-FAE89AC0BCB6 Q39055861-2D750374-891E-4774-93C3-890322E4CC60 Q39279968-42DCF3CF-91AE-44D3-A232-3EA9E3ADD2C1 Q39381251-BAE4265A-71D0-47BF-ADDD-9B50079C145E Q40102561-585DE672-3845-4B2A-9FDF-4B3593778C57 Q40150337-C580E29E-121B-436D-B869-E600AFD1F589 Q40255151-A4C35C0A-380B-4500-9E7B-5E2621C6C2C0 Q40619963-FF2731E3-7A6D-41F8-B7FA-760B6040F6DA Q41591884-C7127E47-A519-464D-A0AB-1CEFA9855866 Q41598765-85C74C44-0DF5-4D4A-BF03-C7C813BB4957 Q41816496-939C7C6F-94DA-4324-9732-61774A4B1CFA Q42368335-FBDA33D6-99C1-4500-A822-A7F2862A21D1 Q47096040-A5AC9F91-6A9D-4674-9DF8-17C35B21A4B9 Q47302497-80BB1C92-3B08-4BB0-B218-CAD8271C3359 Q48223870-B88F8653-DB38-44AE-9047-862BE69C7D0E Q48248214-4137EA1D-66CA-40F3-B4A2-620DD08223F1 Q48296904-C17E5C9F-93AB-4A73-97D5-D5F6D7C21F76 Q48309242-3783DB23-B574-4CEE-888D-9743510155D3 Q49561302-20763E9F-BCD8-4F20-A34A-68BA05127E34 Q50041876-798E38AA-CAF8-4996-82A5-44942F1BAB35 Q50073037-D733695C-B581-4522-B2CB-EDCDF2E2142D Q50101634-E5F50ADB-F27A-4D9A-B9AC-E5BFCC7D80A8

P2860

Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.

http://www.wikidata.org/entity/Q35222112

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Phase 1/2 study of mogamulizum ...... ith cutaneous T-cell lymphoma.

@ast

Phase 1/2 study of mogamulizum ...... ith cutaneous T-cell lymphoma.

@en

type

label

Phase 1/2 study of mogamulizum ...... ith cutaneous T-cell lymphoma.

@ast

Phase 1/2 study of mogamulizum ...... ith cutaneous T-cell lymphoma.

@en

prefLabel

Phase 1/2 study of mogamulizum ...... ith cutaneous T-cell lymphoma.

@ast

Phase 1/2 study of mogamulizum ...... ith cutaneous T-cell lymphoma.

@en

P1433

Q35222112-735A4A2E-D498-4D37-B005-F64EF8D97C25

P1476

Q35222112-33DE5BE1-D82B-4BEC-B065-FBBB9B6B48FF

P2093

Q35222112-0D13A980-0767-4C8E-B94D-F4E46BB43DAA

Q35222112-2634F63A-FE8D-4A4E-8B2F-0667DCA6625C

Q35222112-48499370-6053-430B-B4E4-E0BB7573F2DB

Q35222112-5875FAB3-C712-426A-8967-C1F67749AB95

Q35222112-6688A327-3476-4B2F-8EB5-C6400D174CDF

Q35222112-8DF79C34-A97A-4075-A7F7-F8016F03C158

Q35222112-901A269D-35F9-4D23-9396-ABED394253D1

Q35222112-935B377E-73A8-4805-AC32-C2BF517DD113

Q35222112-9EA5D8F2-FDC4-48F0-8990-62D9D1CF4E19

Q35222112-A5E1C3F5-1E85-4389-A437-0C6FA72BB326

P2860

Q35222112-07673A26-AC63-4471-B7D1-320237541FDC

Q35222112-08FAFA5B-EAE1-43B6-913D-0AC6E0FF7026

Q35222112-0D72B24D-B0F2-4091-8A2F-382149D7D584

Q35222112-198A5FC4-8BFB-4E4F-9FE3-88BB2C45F237

Q35222112-216AE6FB-F3CB-4B68-9328-00150DFC6E83

Q35222112-3089A2D3-ED7D-4288-A378-E9DDBC0C7292

Q35222112-38B205DF-F25E-4464-87D8-BA5340B92E0A

Q35222112-4A45E2DA-4A75-4526-B758-FFBE9DA1E4B2

Q35222112-517B8582-53FA-4D01-9BC8-5B9EC36ABD2D

Q35222112-58DDA371-984F-4CAA-B651-1060B112AAFA

P304

Q35222112-C8B5C4A3-BBDE-479C-B804-BCE60A24DCDB

P31

Q35222112-D0C3D409-3EF4-4423-ADEC-D48CC4E47937

P356

Q35222112-76D80252-B32A-4E5B-B42F-71A31129583C

P407

Q35222112-C14B2654-26E7-49AD-B344-395AAF2334FC

P433

Q35222112-EA54689D-73A9-45D8-A75D-A98BE9F4776A

P478

Q35222112-27447F90-82D0-4169-A3F2-D1D8535B0294

P577

Q35222112-C28ADEAD-9E5D-41ED-813A-0A3A28C4E480

P5875

Q35222112-FBC4CD7A-9413-407C-AB05-E43370273BEA

P698

Q35222112-D5897DAF-B613-4CB0-9DC0-87309509763D

P921

Q35222112-E1E4FC9A-1D1D-43B7-A174-E0182AF5F7A4

P932

Q35222112-578A4E05-3035-46E4-A55A-7F99BB9DCE10

P356

BLOOD-2014-09-600924

P1433

P1476

Phase 1/2 study of mogamulizum ...... ith cutaneous T-cell lymphoma.

@en

P2093

Francine M Foss

http://www.w3.org/2001/XMLSchema#string

Jeffrey L Jorgensen

http://www.w3.org/2001/XMLSchema#string

Karen M Dwyer

http://www.w3.org/2001/XMLSchema#string

Lauren C Pinter-Brown

http://www.w3.org/2001/XMLSchema#string

Li Liu

http://www.w3.org/2001/XMLSchema#string

Lubomir Sokol

http://www.w3.org/2001/XMLSchema#string

Madeleine Duvic

http://www.w3.org/2001/XMLSchema#string

Michael R Kurman

http://www.w3.org/2001/XMLSchema#string

Pramoda Challagundla

http://www.w3.org/2001/XMLSchema#string

Rocco Ballerini

http://www.w3.org/2001/XMLSchema#string

P2860

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.

Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors

Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood.

Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment

Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of

Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009.

Cutaneous CD30 lymphoproliferative disorders and similar conditions: a clinical and pathologic prospective on a complex issue.

Cutaneous T-cell lymphomas: a review of new discoveries and treatments.

P304

1883-1889

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2014-09-600924

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

125

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

271219229

http://www.w3.org/2001/XMLSchema#string

P698

25605368

http://www.w3.org/2001/XMLSchema#string

P921

P932

4375715

http://www.w3.org/2001/XMLSchema#string